Therapy Areas: Respiratory
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
30 June 2025 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials across multiple infectious and respiratory indications, on Monday reported positive topline results from a Phase 2...
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
30 June 2025 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM) (AIM:HCM) (HKEX:13) announced on Monday that it has received approval from the China National Medical Products Administra...
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
25 June 2025 - Hoth Therapeutics Inc (NASDAQ: HOTH), a US-based clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, announced on Tuesda...
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension
23 June 2025 - Merck & Co, Inc (NYSE: MRK), a research-intensive biopharmaceutical company, announced on Monday that its Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) in adults re...
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
20 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration has approved Dupixent (dupilumab) as the first targe...
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
20 June 2025 - Chinese biopharmaceutical company Dizal announced on Thursday the completion of patient enrolment for its WU-KONG28 clinical trial in non-small cell lung cancer (NSCLC).WU-KONG28 is a m...